Log in
Enquire now
Halda Therapeutics

Halda Therapeutics

Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic

OverviewStructured DataIssuesContributors

Contents

haldatx.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Pharmaceutical industry
Pharmaceutical industry
Biotechnology
Biotechnology
Manufacturing
Manufacturing
Location
New Haven, Connecticut
New Haven, Connecticut
B2X
B2B
B2B
Founder
‌
Craig Crews
Number of Employees (Ranges)
11 – 50
Email Address
info@haldathera.com
Phone Number
+14752100212
Investors
Taiho Ventures LLC
Taiho Ventures LLC
Vida Ventures
Vida Ventures
Connecticut Innovations
Connecticut Innovations
Boxer Capital
Boxer Capital
Canaan
Canaan
Total Funding Amount (USD)
126,000,000
Latest Funding Round Date
August 12, 2024
CFO
‌
Scott Phillips
Latest Funding Type
Series B
Series B

Other attributes

Latest Funding Round Amount (USD)
126,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Halda Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.